Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic.
Double-digit organic revenue growth was led by strong volume
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The
Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicleCHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit
Expanded testing menu now detects more intestinal parasites during routine visits
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™
Acquisition strengthens IDEXX’s connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilization
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief
New test brings quantitative cardiac assessment for cats and dogs into everyday workflows
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the
Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.
Strong volume-driven CAG Diagnostics recurring revenue
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today released its 2025 Corporate Responsibility Report, highlighting progress against the company’s goals and commitments.
This
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The
Third menu expansion in four years broadens intestinal parasite detection in routine care
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the expansion of its
Built-in SDMA delivers earlier insights with seamless workflow
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal biomarker, will be built into
Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws
Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic.
Double-digit organic revenue growth was driven by IDEXX
